Samyang and LG Chem partner to develop new mRNA-based cancer therapeutics

Samyang has entered into a strategic partnership agreement with LG Chem to develop new cancer therapeutics using Samyang’s technology, NanoReady.

Samyang will provide LG Chem non-exclusive rights to the NanoReady technology, along with a supply of its key components.

LG Chem will use the technology for the development of innovative mRNA-based cancer therapeutics with maximised therapeutic efficacy.

In return, the company will make an upfront payment and a series of milestone-linked payments to Samyang.

Samyang Holdings Biopharm Division CEO Young-Joon Lee stated: “LG Chem has exceptional research and development expertise in innovative drug development and a number of promising new drug pipelines.

“Taking this recent deal as a driving force, we will continue to strengthen our partnership with LG Chem.

“By leveraging the capabilities of the two companies, we hope to accelerate the development of innovative cancer therapy to significantly improve the lives of suffering cancer patients.”

The company stated that NanoReady provides high versatility to different mRNA molecules.

When combined with mRNA therapeutic molecules developed by LG Chem, the pre-made drug delivery formulation helps to simplify and improve the combination process.

This is expected to shorten the development time of new drugs and to support personalised treatments.

LG Chem Life Sciences company head Ji-Woong Son said: “We hope to maximise success through active collaboration between the two companies, with the aim to provide innovative mRNA-based cancer therapeutics to patients worldwide.”

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Optimise your cell therapy process: a guide to cell thawing

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.

By Cytiva Thematic

By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy